Mara Goldstein
Stock Analyst at Mizuho
(0.53)
# 2462
Out of 5,337 analysts
91
Total ratings
26.00%
Success rate
-9.54%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IOVA Iovance Biotherapeut... | Maintains: Outperform | 30 10 | 1.71 | 484.8% | 5 | May 12, 2025 | |
VSTM Verastem | Maintains: Outperform | 9 8 | 7.08 | 12.99% | 7 | Apr 9, 2025 | |
KURA Kura Oncology | Maintains: Strong Buy | 26 32 | 5.73 | 458.46% | 2 | Jan 31, 2024 | |
RCUS Arcus Biosciences | Maintains: Buy | 51 42 | 8.55 | 391.23% | 4 | Jan 30, 2024 | |
XNCR Xencor | Maintains: Buy | 59 50 | 8.16 | 512.75% | 2 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 45 | 9.27 | 385.44% | 1 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 82 77 | 61.16 | 25.9% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 8 7 | 1.27 | 451.18% | 3 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 8 | 0.96 | 733.33% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 20 12 | 0.4 | 2900% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 6 | 0.71 | 745.07% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 4 | 3.62 | -3.31% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 40 30 | n/a | n/a | 3 | May 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 0.15 | 7900% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 10 20 | 1.27 | 1474.8% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 130 | 73.52 | 76.82% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 2.35 | -14.89% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 20 2 | n/a | n/a | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 12 | 1.23 | 875.61% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 9 | 0.27 | 3233.33% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | n/a | n/a | 1 | Oct 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 13 10 | n/a | n/a | 2 | Sep 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 96 | n/a | n/a | 4 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 14 20 | 29.99 | -33.31% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 48 | 8.31 | 477.62% | 4 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 135 45 | 18.95 | 137.47% | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 22800 6000 | n/a | n/a | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 14 | 3.29 | 325.53% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 9 | n/a | n/a | 1 | Sep 14, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 15 | n/a | n/a | 1 | Jul 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 16 6 | n/a | n/a | 2 | Apr 18, 2017 |